Maria Eugenia Socias

Maria Eugenia Socias

Auto-generated profile, based on publicly available information

Maria Eugenia Socias

British Columbia Centre on Substance Use Vancouver Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MLMatthew K. Laing
Matthew K. Laing
LTLianping Ti
Lianping Ti
AMAllison Marmel
Allison Marmel
STSamuel Tobias
Samuel Tobias
ASAaron M. Shapiro
Aaron M. Shapiro
MSM. Eugenia Socías
M. Eugenia Socías

3 January 2020 in Addiction
Verified
Journal Article
Closed access
PDF file
MPMicah Piske
Micah Piske
HZHaoxuan Zhou
Haoxuan Zhou
JMJeong E Min
Jeong E Min
NHNatt Hongdilokkul
Natt Hongdilokkul
LPLindsay A Pearce
Lindsay A Pearce
BNBohdan Nosyk
Bohdan Nosyk

20 October 2021 in The American Journal of Drug and Alcohol Abuse
Verified
Journal Article
Closed access
ofer amramofer amram
ofer amram
SASolmaz Amiri
Solmaz Amiri
VPVictoria Panwala
Victoria Panwala
RLRobert Lutz
Robert Lutz
PJPaul J. Joudrey
Paul J. Joudrey
ESEugenia Socias
Eugenia Socias
Background: In response to the COVID-19 pandemic, the US Substance Abuse and Mental Health Services Administration (SAMHSA) allowed for an increase in methadone take-home doses for the treatment of...

1 October 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MSM. Eugenia Socías
M. Eugenia Socías
MKMohammad Karamouzian
Mohammad Karamouzian
SPStephanie Parent
Stephanie Parent
JBJosé Barletta
José Barletta
KBKathleen Bird
Kathleen Bird
LTLianping Ti
Lianping Ti

20 September 2018 in Addiction
Verified
Journal Article
Closed access
PDF file
MSMaria Eugenia Socías
Maria Eugenia Socías
EWEvan Wood
Evan Wood
SLStephanie Lake
Stephanie Lake
SNSeonaid Nolan
Seonaid Nolan
NFNadia Fairbairn
Nadia Fairbairn
MMMichael John S. Milloy
Michael John S. Milloy

18 March 2021 in American Journal of Public Health
Verified
Journal Article
Closed access
JMJanice Mok
Janice Mok
MMM.-J. Milloy
M.-J. Milloy
CGCameron Grant
Cameron Grant
SLStephanie Lake
Stephanie Lake
KDKora DeBeck
Kora DeBeck
MSM. Eugenia Socías
M. Eugenia Socías
Objectives. To characterize the prevalence and reasons for the use of cannabis as a strategy to reduce the harms arising from other substances. Methods. We drew data about recent cannabis use and intentions from 3 prospective cohort studies of marginalized people who use drugs based in Vancouver, Canada, from June 2016 to May 2018. The primary outcome was “use of cannabis for harm reduction,” defined as using cannabis for substitution for licit or illicit substances such as heroin or other opioids, cocaine, methamphetamine, or alcohol; treating withdrawal; or coming down off other drugs. Results. Approximately 1 in 4 participants reported using cannabis for harm reduction at least once during the study period. The most frequent reasons included substituting for stimulants (50%) and substituting for illicit opioids (31%). Conclusions. The use of cannabis for harm reduction is a common strategy among people who use drugs in our setting. Further research into the factors associated with this strategy is needed. Better characterization of the risks and benefits of substitution strategies, including for opioids and stimulants, may prompt new treatment options for PWUD.